Paradoxical rising cytomegalovirus antigenemia during preemptive ganciclovir therapy in hematopoietic stem cell transplant recipients: Incidence, risk factors, and clinical outcomes

Journal of Clinical Microbiology

Volumn 49, Issue 12, 2011, Pages 4179-4184

  Park, So Youn ^a   Lee, Sang Oh ^a   Choi, Sang Ho ^a   Kim, Yang Soo ^a   Woo, Jun Hee ^a   Sung, Heungsup ^a   Kim, Mi Na ^a   Kim, Dae Young ^a   Lee, Jung Hee ^a   Lee, Je Hwan ^a   Lee, Kyoo Hyung ^a   Kim, Sung Han ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; FLUDARABINE; GANCICLOVIR; STEROID; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HUMAN; INCIDENCE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; TREATMENT DURATION; VIRAL CLEARANCE;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CHEMOPREVENTION; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; VIREMIA; YOUNG ADULT;

EID: 82455174870     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.05464-11     Document Type: Article

References (18)

1. Boeckh, M., et al. 1996. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 88:4063-4071. (Pubitemid 26383133)
2. Boeckh, M., and P. Ljungman. 2003. Cytomegalovirus infection after hemopoietic stem cell transplantation, p. 286. In R. A. Bowden, P. Ljungman, and C. V. Paya (ed.), Transplant infections, 2nd ed. Lippincott Williams & Wilkins, Philadelphia, PA.
3. Boeckh, M., and W. G. Nichols. 2004. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood 103: 2003-2008. (Pubitemid 38326213)
4. Buyck, H. C., P. D. Griffiths, and V. C. Emery. 2010. Human cytomegalovirus (HCMV) replication kinetics in stem cell transplant recipients following anti-HCMV therapy. J. Clin. Virol. 49:32-36.
5. Einsele, H., et al. 1995. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 86:2815-2820.
6. Gane, E., et al. 1997. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. Lancet 350:1729-1733. (Pubitemid 28036671)
7. Gerna, G., et al. 1998. Rising levels of human cytomegalovirus (HCMV) antigenemia during initial antiviral treatment of solid-organ transplant recipients with primary HCMV infection. J. Clin. Microbiol. 36:1113-1116. (Pubitemid 28146309)
8. Gerna, G., et al. 2003. In vitro model for the study of the dissociation of increasing antigenemia and decreasing DNAemia and viremia during treatment of human cytomegalovirus infection with ganciclovir in transplant recipients. J. Infect. Dis. 188:1639-1647. (Pubitemid 38010673)
9. Gerna, G., et al. 2005. Rising antigenemia levels may be misleading in pre-emptive therapy of human cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients. Haematologica 90:526-533.
10. Gilbert, C., et al. 2001. Lack of emergence of cytomegalovirus UL97 mutations conferring ganciclovir (GCV) resistance following preemptive GCV therapy in allogeneic stem cell transplant recipients. Antimicrob. Agents Chemother. 45:3669-3671. (Pubitemid 33107905)
11. Jang, E. Y., et al. 2009. Diagnostic performance of the cytomegalovirus (CMV) antigenemia assay in patients with CMV gastrointestinal disease. Clin. Infect. Dis. 48:e121-e124.
12. Limaye, A. P. 2002. Ganciclovir-resistant cytomegalovirus in organ transplant recipients. Clin. Infect. Dis. 35:866-872.
13. Ljungman, P., P. Griffiths, and C. Paya. 2002. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin. Infect. Dis. 34:1094-1097. (Pubitemid 34289682)
14. Lurain, N. S., and S. Chou. 2010. Antiviral drug resistance of human cytomegalovirus. Clin. Microbiol. Rev. 23:689-712.
15. Nichols, W. G., et al. 2001. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes. Blood 97:867-874. (Pubitemid 32154267)
16. Paya, C. V. 2001. Prevention of cytomegalovirus disease in recipients of solid-organ transplants. Clin. Infect. Dis. 32:596-603. (Pubitemid 32565001)
17. Reusser, P., L. D. Fisher, C. D. Buckner, E. D. Thomas, and J. D. Meyers. 1990. Cytomegalovirus infection after autologous bone marrow transplantation: occurrence of cytomegalovirus disease and effect on engraftment. Blood 75:1888-1894. (Pubitemid 20161506)
18. Zaia, J. A., et al. 1997. Late cytomegalovirus disease in marrow transplantation is predicted by virus load in plasma. J. Infect. Dis. 176:782-785. (Pubitemid 27360551)